The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Empliciti Market By 2030?
The growth observed during the historical timeframe can be linked to the escalating incidence of multiple myeloma, the constrained effectiveness of conventional chemotherapy, the initial positive results from monoclonal antibody medications, the proliferation of oncology treatment facilities, and the augmented financial commitment to cancer research.
Anticipated growth in the forecast period is driven by the wider acceptance of immunotherapy protocols, an expanding pipeline of monoclonal antibodies, improved survival rates prompting demand for long-term treatments, favorable reimbursement conditions for oncology biologics, and ongoing advancements in immune-based drug development.
Key trends expected during this period encompass combination monoclonal antibody therapies, cancer treatments specifically targeting the immune system, a movement towards personalized care for multiple myeloma, the increasing application of immunotherapy in oncology, and the growing adoption of long-term biologic regimens.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20055&type=smp
What Market Drivers Are Helping Shape The Empliciti Market Expansion?
The growing incidence of multiple myeloma is projected to propel the expansion of the empliciti market in the future. Multiple myeloma is a cancer affecting plasma cells, a type of white blood cell found in bone marrow, leading to abnormal cell proliferation and potential damage to bones, kidneys, and the immune system. The prevalence of this condition is influenced by an aging population and advancements in diagnostic methods. Empliciti specifically targets the SLAMF7 protein on myeloma and natural killer (NK) cells, thereby enhancing the immune system’s capacity to identify and eliminate cancer cells. It improves NK cell activity and fosters antibody-dependent cellular cytotoxicity (ADCC), which helps to slow disease progression when used in combination with other treatments. For example, in August 2024, the American Cancer Society, a US-based non-profit organization, reported that in 2024, approximately 35,780 new cases of multiple myeloma were diagnosed in the United States, with 19,520 cases in men and 16,260 in women. Additionally, about 12,540 deaths are predicted, including 7,020 in men and 5,520 in women. Therefore, the increasing prevalence of multiple myeloma will drive the growth of the empliciti market. Rising demand for targeted cancer therapies is a significant factor fueling the growth of the empliciti market in the coming years. Targeted cancer therapies are designed to attack cancer cells by identifying specific molecular markers, thus minimizing harm to healthy cells. The increasing need for these therapies is due to advancements in precision medicine, the growing incidence of cancer, improved treatment effectiveness, and a greater emphasis on reducing side effects. Empliciti targets SLAMF7, a protein found on multiple myeloma and immune cells, boosting the immune system’s ability to combat cancer. This precise approach enhances effectiveness while sparing healthy tissues. For instance, in June 2024, according to the Royal College of Radiologists, a UK-based professional body specializing in clinical oncology and clinical radiology, the demand for systemic anti-cancer therapies (SACT), which includes chemotherapy, saw a growth of 6-8% in 2023. Consequently, the rising demand for targeted cancer therapies will propel the growth of the empliciti market.
How Is Segment Classification Applied In The Empliciti Market?
The empliciti market covered in this report is segmented –
1) By Indication: Active Multiple Myeloma, Smoldering Multiple Myeloma
2) By Drug Class: Monoclonal Antibodies, Immunomodulatory Agents, Proteasome Inhibitors
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Which Companies Form The Competitive Landscape Of The Empliciti Market?
Major companies operating in the empliciti market are Bristol-Myers Squibb Company
Access The Complete Empliciti Market Report:
https://www.thebusinessresearchcompany.com/report/empliciti-global-market-report
Which Region Accounts For The Highest Share Of The Empliciti Market?
North America was the largest region in the empliciti market in 2025. The regions covered in the empliciti market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model